How Johnson & Johnson Stock Gained 60%
Between June 8, 2025, and March 5, 2026, Johnson & Johnson (JNJ) soared 58%, fueled by robust revenue gains and a surge in investor confidence amid transformative growth in MedTech and oncology. Despite patent headwinds, innovative drug sales and a landmark FDA approval kept momentum strong—yet a cautious pullback hinted at shifting tides.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 6082025 | 3052026 | Change | |
|---|---|---|---|
| Stock Price ($) | 152.1 | 239.6 | 57.5% |
| Total Revenues ($ Mil) | 89,331.0 | 94,193.0 | 5.4% |
| Net Income Margin (%) | 24.4% | 28.5% | 16.6% |
| P/E Multiple | 16.8 | 21.5 | 28.2% |
| Shares Outstanding (Mil) | 2,407.2 | 2,407.7 | -0.0% |
| Cumulative Contribution | 57.5% |
So what is happening here? The 58% stock surge reflects solid revenue growth of 5.4%, improved net income margin by 17%, and a 28% higher P/E multiple, signaling growing investor confidence ahead of key developments.
Here Is Why Johnson & Johnson Stock Moved
- Does Johnson & Johnson Stock Still Have Room to Run?
- Stronger Bet Than Viatris Stock: LLY, JNJ Deliver More
- Should You Pay Attention To Johnson & Johnson Stock’s Momentum?
- Does Johnson & Johnson Stock Have More Upside?
- Why Johnson & Johnson Stock Jumped 60%?
- Does Johnson & Johnson Stock Still Have Room to Run?
- Stelara LOE Defied: Innovative Medicine sales grew organically by 4.1% in 2025 despite a 1040bps headwind from Stelara’s patent loss, proving new drug portfolio strength.
- MedTech Growth Pivot: The Cardiovascular unit sales surged 15.8% in 2025, as strategic acquisitions successfully transformed the MedTech segment into a high-growth driver.
- Oncology Franchise Power: The oncology portfolio delivered ~21% operational growth in 2025, with Darzalex alone exceeding $14B, creating a durable, high-margin revenue base.
- Strong 2026 Guidance: Management guided to $100B+ revenue for 2026, implying 5.7%-6.7% operational growth and quantifying the earnings power of its new product cycle.
- Pipeline Validation: The FDA approval of a new blood cancer drug on March 5, 2026, confirms the R&D engine’s ability to bring new, high-value assets to the market.
Current Assesment Of JNJ Stock
The core investment debate is centered around: Can accelerating growth from the innovative pipeline (Oncology, MedTech) fully offset the material revenue erosion from Stelara’s loss of exclusivity and absorb major litigation/regulatory risks?
The prevailing sentiment appears to be neutral. Sentiment is pinned at Neutral. The impressive, accelerating growth in the new portfolio (+) is in a direct tug-of-war with the massive, quantifiable Stelara patent cliff (-) and the unquantifiable talc litigation overhang (-). The company is executing well, but the headwinds are structural.
| Bull View | Bear View |
|---|---|
| Strong growth in Darzalex, Carvykti, and Tremfya, plus a deep pipeline, will overwhelm the Stelara headwind, leading to re-accelerated growth and a higher multiple in 2026. | The ~50% decline in the ~$10B Stelara franchise, combined with unquantified talc liability and IRA margin pressure, creates an insurmountable drag on growth and sentiment. |
Navigating the competing bull and bear cases of any single stock carries inherent volatility. Managing that idiosyncratic risk requires a broader portfolio framework.
Portfolios Over Individual Stock Picks
Individual stocks can soar or tank but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside and mitigate the downside associated with any individual stock.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.